FDA Caught a Major Drug Supplier Tampering With Batch Records. Again.

When the same pharmaceutical manufacturer receives multiple FDA enforcement actions across multiple facilities in just a few years, it stops being a compliance problem. It becomes a pattern. And patterns tell you something about culture that no corrective action plan can paper over.

One of the largest generic drug suppliers to the U.S. market is back in FDA’s crosshairs. Again.

CDER issued a Warning Letter in March 2026 following an inspection that uncovered serious cGMP violations – including a data integrity finding that should alarm every quality professional and procurement team that sources from contract manufacturers.

This is not the company’s first Warning Letter. It is not their second. The enforcement history here goes back years, spans multiple facilities, and includes some of the most egregious documentation failures FDA has made public in recent memory.

The problem with the U.S. generics supply chain is not theoretical. It shows up in drug shortages. It shows up in recalled products. And it shows up in Warning Letters like this one – where the same quality culture failures keep producing the same regulatory outcomes at different sites of the same company.

What FDA found this time – and what it means for companies that source from manufacturers with enforcement history – is detailed in the full analysis on The Investigator’s Lens.

Is Your Contract Manufacturer on FDA’s Enforcement Radar? If you source APIs or finished products from Indian generics manufacturers, your supplier qualification program may not be going deep enough. FD-AID LLC conducts supplier quality assessments and data integrity gap analyses grounded in real FDA enforcement experience. Contact devaughn@fdaid.org to schedule a consultation before FDA’s next inspection cycle begins.

Read the full analysis – including the complete enforcement timeline, the specific violations FDA cited, and what your procurement and quality teams need to do now:

The Investigator’s Lens: https://devaughnedwards.substack.com/p/fda-caught-intas-pharmaceuticals

DeVaughn Edwards is a former FDA Investigator with 14 years of federal service and 13 years as a pharmaceutical quality executive. He is the founder and Principal Consultant of FD-AID LLC (fdaid.org).

devaughn@fdaid.org | devaughn@gmail.com

Copyright FDAID LLC 2026